Evolution of First-Line Immune Checkpoint Inhibition in Advanced or Metastatic Solid TumorsNovember 8th 2022
This digital series explores the evolving first-line treatment landscape of advanced or metastatic solid tumors, including non-small cell lung cancer, with an emphasis on the use of immune checkpoint inhibitors alone or in combination with other treatment modalities.
Addressing Myelotoxicity as a Consequence of Treatment for Extensive-Stage Small Cell Lung CancerSeptember 20th 2021
This digital series raises awareness regarding the challenges in treating extensive-stage small cell lung cancer through a review of the current treatment landscape, recently approved therapeutics, and emerging options for addressing the consequences of treatment.
New Precision Medicine Approaches in Advanced Prostate CancerAugust 30th 2021
This digital series raises awareness regarding the evolving spectrum of precision medicine in advanced prostate cancer through a review of the genomic testing and biomarker landscape as well as the rapidly developing treatment armamentarium, with an emphasis on the potential impact of these newer therapies.